
Andrew S Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1467066/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Childhood cancer survival and avoided deaths in Australia, 1983–2016. Paediatric and Perinatal Epidemiology, 2023, 37, 81-91.	1.7	7
2	Changes in cancer incidence and survival among Aboriginal and Torres Strait Islander children in Australia, 1997–2016. Pediatric Blood and Cancer, 2022, 69, e29492.	1.5	2
3	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. British Journal of Cancer, 2022, 127, 908-915.	6.4	2
4	Tumor cell invasion into Matrigel: optimized protocol for RNA extraction. BioTechniques, 2021, 70, 327-335.	1.8	0
5	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10â€year review. Pediatric Blood and Cancer, 2021, 68, e29275.	1.5	10
6	Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 2021, 138, 2293-2298.	1.4	5
7	Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma. Journal of Visualized Experiments, 2021, , .	0.3	1
8	Second primary cancers in people who had cancer as children: an Australian Childhood Cancer Registry populationâ€based study. Medical Journal of Australia, 2020, 212, 121-125.	1.7	22
9	The incidence of childhood cancer in Australia, 1983–2015, and projections to 2035. Medical Journal of Australia, 2020, 212, 113-120.	1.7	33
10	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nature Medicine, 2020, 26, 1742-1753.	30.7	185
11	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
12	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective Iâ€BFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	2.5	12
13	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Advances, 2020, 4, 1478-1491.	5.2	15
14	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
15	Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003â€2013. Pediatric Blood and Cancer, 2019, 66, e27915.	1.5	34
16	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	4.4	73
17	Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Pediatric Blood and Cancer, 2019. 66. e27812.	1.5	6
18	The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network. Biopreservation and Biobanking, 2019, 17, 95-97.	1.0	2

ANDREW S MOORE

#	Article	IF	CITATIONS
19	Stage at diagnosis for children with blood cancers in Australia: Application of the Toronto Paediatric Cancer Stage Guidelines in a populationâ€based national childhood cancer registry. Pediatric Blood and Cancer, 2019, 66, e27683.	1.5	9
20	Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10â€year review. Pediatric Blood and Cancer, 2019, 66, e27564.	1.5	31
21	<i>PTEN</i> deletion drives acute myeloid leukemia resistance to MEK inhibitors. Oncotarget, 2019, 10, 5755-5767.	1.8	9
22	Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study. The Lancet Child and Adolescent Health, 2018, 2, 173-179.	5.6	18
23	The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion. Scientific Reports, 2018, 8, 1032.	3.3	17
24	Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2018, 20, 389-397.	2.8	25
25	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527
26	Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia. Molecular Cancer Research, 2018, 16, 279-285.	3.4	27
27	Therapyâ€related acute myeloid leukemia following treatment for cancer in childhood: A populationâ€based registry study. Pediatric Blood and Cancer, 2018, 65, e27410.	1.5	12
28	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	27.8	236
29	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
30	Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. Cancer Chemotherapy and Pharmacology, 2017, 80, 15-25.	2.3	10
31	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
32	EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia, 2017, 31, 1779-1787.	7.2	29
33	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 2017, 64, e26351.	1.5	20
34	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 2017, 102, e490-e493.	3.5	52
35	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
36	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 2017, 408, 92-101.	7.2	23

ANDREW S MOORE

#	Article	IF	CITATIONS
37	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	1.8	16
38	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
39	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197
40	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
41	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
42	Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 2016, 7, 47465-47478.	1.8	39
43	The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997–2008: A report from the Australian Paediatric Cancer Registry. Pediatric Blood and Cancer, 2015, 62, 1664-1666.	1.5	12
44	Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia. Leukemia Research, 2015, 39, 435-444.	0.8	12
45	Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. Blood, 2015, 126, 1644-1644.	1.4	2
46	EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. PLoS ONE, 2015, 10, e0130692.	2.5	20
47	Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. Cell Stem Cell, 2014, 15, 775-790.	11.1	74
48	<i>BIRC5</i> (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2014, 61, 647-652.	1.5	27
49	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
50	Novel therapies for children with acute myeloid leukaemia. Leukemia, 2013, 27, 1451-1460.	7.2	47
51	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine, 2013, 8, 4361.	6.7	18
52	The Survivin Suppressant YM155 (Sepantronium Bromide) Has Potent Pre-Clinical Activity Against Pediatric Acute Myeloid Leukemia. Blood, 2013, 122, 3957-3957.	1.4	0
53	Optimization of Imidazo[4,5- <i>b</i>]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2012, 55, 8721-8734.	6.4	61
54	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia, 2012, 26, 1462-1470.	7.2	105

ANDREW S MOORE

#	Article	IF	CITATIONS
55	A stable-isotope HPLC–MS/MS method to simplify storage of human whole blood samples for glutathione assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 898, 136-140.	2.3	17
56	Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limitedâ€sampling, population modelling approach. Journal of Paediatrics and Child Health, 2011, 47, 875-882.	0.8	53
57	Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research, 2011, 35, 1273-1275.	0.8	6
58	Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia , 2011, , .		3
59	Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia, 2010, 24, 671-678.	7.2	82
60	Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. Blood, 2010, 116, 3289-3289.	1.4	1
61	Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia. Blood, 2010, 116, 1818-1818.	1.4	0
62	Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998–2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Medical Journal of Australia, 2009, 190, 121-125.	1.7	39
63	Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva. Pediatric Blood and Cancer, 2009, 53, 669-671.	1.5	3
64	Vincristine: Can its therapeutic index be enhanced?. Pediatric Blood and Cancer, 2009, 53, 1180-1187.	1.5	63
65	Letters to the Editor. Journal of Paediatrics and Child Health, 2007, 43, 415-416.	0.8	0